Trends in the Development of New Drugs for the Treatment of Benign Prostatic Hyperplasia
November 2006
in “
Current Medicinal Chemistry
”
α₁-adrenoceptor antagonists 5α-reductase inhibitors uroselective α₁-AR antagonists non-steroidal 5α-reductase inhibitors combined inhibitors endothelins androgen receptor antagonists growth factors estrogens phosphodiesterase isoenzymes phytomedicines alpha-1 blockers 5-alpha reductase inhibitors uroselective alpha-1 blockers non-steroidal 5-alpha reductase inhibitors androgen blockers PDE inhibitors herbal medicines
Studysummary This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer